Company profile
VIRIDIAN THERAPEUTICS, INC.\DE
NASDAQ:VRDNBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LUMVOA | approved | — | 0 | — |
| ELEGROBART | phase3 | — | 4 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06384547 | phase3 | completed | 2024-05-23 | 2025-05-01 | Viridian Therapeutics, Inc. | A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) |
| NCT06812325 | phase3 | active_not_recruiting | 2025-02-03 | 2026-04-22 | Viridian Therapeutics, Inc. | A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) |
| NCT07155668 | phase3 | completed | 2025-07-01 | 2026-05-28 | Viridian Therapeutics, Inc. | A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) |
| NCT05176639 | phase3 | completed | 2022-11-16 | 2024-07-15 | Viridian Therapeutics, Inc. | A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED) |
| NCT06625411 | phase3 | active_not_recruiting | 2024-08-27 | 2026-02-12 | Viridian Therapeutics, Inc. | An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 761530 | 2026-06-26 | BLA | VIRIDIAN THERAPEUTICS, INC. | |||||
Loading… | ||||||||